Tests BPC 157 against alloxan-induced gastric lesions in rats and mice (diabetogenic alloxan, which also causes GI damage). BPC 157 (μg or ng/kg, IP, co-administered with alloxan) significantly attenuated gastric lesions at 24 hours, 1 week, and 2 weeks post-alloxan in both species and at both doses. Without BPC 157, lesions were consistently present and sustained. Extends BPC 157's gastric cytoprotection to chemically-induced damage in the context of diabetes model induction.
Abstract
A diabetogenic alloxan regimen produced lesions in all stomachs of treated animals, either rats (200 mg x kg(-1) s.c.) or mice (400 mg x kg(-1) i.p.). In control animals, the lesions, when developed (i.e. 24 h following application), appear to be quite sustained, and consistently present also after 1 or 2 weeks. The application of the pentadecapeptide BPC 157 (10 microg or 10 ng x kg(-1) i.p. coadministered together with alloxan) would significantly attenuate these lesions' appearance. This beneficial effect seems to be present in either rats or mice and in either of the tested intervals. Importantly, the beneficial effect seems to be shared by both microgram and nanogram regimens.